The Pediatric Solid Tumor Program at the Cancer Center at The Children's Hospital of Philadelphia consists of a multidisciplinary team of experts working together to develop a care plan for your child's hepatoblastoma. Many of our oncologists are also on the forefront of researching new therapies for treatment of hepatoblastoma.
Hepatoblastoma is a rare tumor (an abnormal tissue growth) that originates in cells in the liver. It is the most common cancerous (malignant) liver tumor in early childhood. Most hepatoblastoma tumors begin in the right lobe of the liver. Hepatoblastoma cancer cells also can spread (metastasize) to other areas of the body. The most common site of metastasis is the lungs.
Hepatoblastoma primarily affects children from infancy to about 5 years of age. Most cases appear during the first 18 months of life. Hepatoblastoma affects white children more frequently than black children, and is more common in boys than girls up to about age 5, when the gender difference disappears. It occurs more frequently in children who were born very prematurely (early) with very low birth weights.
Although the exact cause of liver cancer is unknown, there are a number of genetic conditions that are associated with an increased risk for developing hepatoblastoma. They include:
Children who are exposed to hepatitis B infection at an early age, or those who have biliary atresia, are also at increased risk for developing liver cancer.
The signs and symptoms of pediatric hepatoblastoma often depend on the size of the tumor and whether it has spread to other parts of the body. Symptoms may include:
After taking a complete medical history and doing a physical examination of your child, we may use the following tests:
Treatment for hepatoblastoma is aimed at removing (resecting) as much of the tumor as possible. Liver tissue can regenerate after a portion is removed.
Most hepatoblastomas also require treatment with chemotherapy to shrink the tumor before surgery. This makes it easier and safer for the surgeon to remove the mass. Chemotherapy is also given after surgery to minimize the chance of recurrence (cancer regrowth).
As with any cancer, prognosis and long-term survival can vary greatly from child to child. Prompt medical attention and aggressive therapy are important for the best prognosis. Continuous follow-up care is essential for a child diagnosed with hepatoblastoma because side effects of radiation and chemotherapy may occur, as well as second malignancies.
Some children treated for cancer develop complications years later. Our Cancer Survivorship Program will provide you with information about the potential long-term effects of the specific treatment your child received, including ways of monitoring and treating these effects.
Reviewed by: Edward F. Attiyeh, MD, The Children's Hospital of Philadelphia
Date: November 2009
To schedule an appointment or request a second opinion, call 215-590-2810.
You may also contact us online with comments, questions, feedback and requests for information.
Existing patients or family members, please call
To schedule an initial appointment or request a 2nd opinion